Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
Forest Laboratories, Inc. and its development partner for desmoteplase, PAION AG , today announced that the independent Data Monitoring Committee for the DIAS-2 Phase IIB/III study met and informed the Steering Committee and the Companies that it has reviewed the cumulative data from the study provided by the Companies and recommended the resumption of patient enrollment into DIAS-2 with no
Source: biz.yahoo.com
<< Home